Literature DB >> 3655404

Antigenic variation in rabies and rabies-related viruses: cross-protection independent of glycoprotein-mediated virus-neutralizing antibody.

B Dietzschold1, M Tollis, C E Rupprecht, E Celis, H Koprowski.   

Abstract

Immunization experiments with vaccines prepared from the PM and ERA strains of rabies virus demonstrated that in mice, only ERA vaccine primes for an anamnestic response to the rabies-related strain Duvenhage (DUV6); in rabbits, both ERA and PM vaccines induced immunologic memory to DUV6 virus. In mice, ERA vaccine, but not an equal concentration of PM vaccine, conferred protection against a lethal challenge infection with DUV6 virus. This result indicated that the protective activity correlated with the vaccine's ability to induce immunologic memory. A vaccine prepared from a sequentially selected, neutralization-resistant, multiple-variant virus conferred protection against challenge with the parental strain, a result indicating that antigenic variation of the glycoprotein may not be the sole factor in determining the relative efficacy of rabies prophylaxis. We found no correlation between titers of neutralizing antibody and mortality rates in mice immunized with purified glycoprotein from these viruses.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3655404     DOI: 10.1093/infdis/156.5.815

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine.

Authors:  J H Nunberg; M V Doyle; S M York; C J York
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

Review 2.  The glycoprotein G of rhabdoviruses.

Authors:  J M Coll
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

3.  Cells with natural killer activity in human rabies.

Authors:  T Panpanich; T Hemachudha; S Piyasirisilp; S Manatsathit; H Wilde; P Phanuphak
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

4.  T and B cell human responses to European bat lyssavirus after post-exposure rabies vaccination.

Authors:  M Herzog; C Fritzell; M Lafage; J A Montaño Hirose; D Scott-Algara; M Lafon
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

5.  A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein.

Authors:  Ralf Amann; Jörg Rohde; Ulrich Wulle; Douglas Conlee; Rudiger Raue; Olivier Martinon; Hanns-Joachim Rziha
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

6.  Expression of the rabies virus nucleoprotein in plants at high-levels and evaluation of immune responses in mice.

Authors:  Irene Perea Arango; Elizabeth Loza Rubio; Edith Rojas Anaya; Teresa Olivera Flores; Luis Gonzalez de la Vara; Miguel Angel Gómez Lim
Journal:  Plant Cell Rep       Date:  2008-02-13       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.